CytomX Therapeutics (CTMX)
Develops tumor-localized, conditionally activated oncology biologics through its PROBODY platform.
Something off on this page? Send us feedback.
Develops tumor-localized, conditionally activated biologics with PROBODY masking technology. The clinical-stage oncology portfolio centers on Varseta-M (CX-2051) and CX-801, with research collaborations rather than sales of approved medicines.
Develops conditionally activated biologics designed to localize in the tumor microenvironment through PROBODY masking technology. The design premise is intended to limit activity in healthy tissue. Internal clinical-stage programs include Varseta-M (CX-2051) and CX-801, alongside collaborations with Amgen, Bristol Myers Squibb, Regeneron, and Moderna.
Operates in a single U.S. reportable segment and has no current product-sales revenue. The model combines internal oncology development with external research and development collaborations rather than selling approved medicines.
A 2025 restructuring narrowed the focus to Varseta-M, CX-801, and research collaborations. Progress and resource needs are shaped by clinical trials, research activities, and the execution of collaboration arrangements.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 19, 2026 | Wolfe Research | Target | Target: — | Target: $6 |
| May 11, 2026 | H.C. Wainwright | Target | Target: — | Target: $11 |
| Mar 18, 2026 | Jefferies | Reiterate | Rating: —Target: $8 | Target: $16 |
| Mar 16, 2026 | Oppenheimer | Target | Target: $7 | Target: $12 |
| Mar 16, 2026 | JP Morgan | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $330.3M · Total debt $5.7M · Total assets $381.2M · Shareholders' equity $302.1M
- Revenue
- $1.4M
- Operating income
- −$23.8M
- Net income
- −$20.7M
No dividends on record.
| Institutions | ≈ 97.40% | 212.23M shares | |
|---|---|---|---|
| 189 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.92% | 2.01M shares | |
| 7 holders · as of Aug 5, 2026 | |||
| Strategic holders | 5.72% | 12.46M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 104.04% | ||
217.90M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 104.04%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 15.01% | 32.71M | as of Jun 30, 2026 |
Kynam Capital Management, LPInstitution | 9.96% | 21.70M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.06% | 17.56M | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 6.92% | 15.08M | as of Jun 30, 2026 |
Longitude Capital Partners V, LLCStrategic | 5.72% | 12.46M | filed May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 15, 2026 | Christopher Ogden | officer: Chief Financial Officer | −1,624 | $3.05 |
| Mar 17, 2026 | Christopher Ogden | officer: Chief Financial Officer | −19,323 | $6.42 |
| Mar 17, 2026 | Marcia Belvin | officer: SVP, Chief Scientific Officer | −31,492 | $6.42 |
| Mar 17, 2026 | Sean A. McCarthy | director, officer: CEO | −118,969 | $6.42 |
| Mar 17, 2026 | Yu-Waye Chu | officer: Chief Medical Officer | −21,279 | $6.42 |
- Adagene (ADR)
Masked CTLA-4 immunotherapy in MSS metastatic CRC
- Werewolf Therapeutics
Conditionally activated cytokines and masked T-cell engagers
- Xilio Therapeutics
Masked immuno-oncology platform with cytokine and TCE programs
- Janux Therapeutics
Double-masked tumor-activated T-cell engagers in Phase 1
- Xencor
Tumor-targeted CD3 bispecifics with CRC expansion cohorts
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CytomX Therapeutics | $2.80 | −4.74% | $640.0M | — | — | 35.0 | −92.4% |
| Adagene (ADR) | $2.97 | −8.05% | $121.6M | — | — | 13.1 | — |
| Werewolf Therapeutics | $0.9767 | −0.54% | $47.7M | — | — | 2.3 | — |
| Xilio Therapeutics | $8.94 | −1.11% | $59.4M | — | — | 0.9 | +131.1% |
| Janux Therapeutics | $16.80 | −3.84% | $1.07B | — | — | 33.4 | — |
| Xencor | $24.58 | −2.31% | $1.87B | — | — | 17.8 | +17.5% |
| Median | — | — | 13.1 | +74.3% |